Oncology Startups
22 companies tagged Oncology, with their investors and founders.
FidoCure provides precision medicine for canine oncology, offering genetic sequencing and targeted therapies that enable veterinarians to treat dogs with cancer. It operates a US network of veterinary clinics and oncologists for both cancer diagnostics and treatment.
17 investors
Kopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.
12 investors
Notable Labs operates a personalized drug discovery platform that tests combinations of FDA-approved drugs against a patient's own cancer cells to identify treatment options, focusing initially on relapsed and refractory blood cancer. It runs a highly automated lab with custom software and works with relapsed/refractory cancer patients as well as pharma and biotech partners.
12 investors
Numerion Labs develops machine learning algorithms for drug discovery, combining computational chemistry, structural biology, and medicinal chemistry. It builds AI-driven platforms aimed at accelerating the identification of new medicines.
7 investors
Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.
7 investors
Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.
6 investors
CCG.ai develops software for data-driven precision oncology, using clinical and genomic data to identify biomarkers of treatment response and help oncologists choose cancer therapies. It serves clinicians and oncologists in the cancer treatment field.
6 investors
Granza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.
6 investors
Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.
6 investors
Clear Gene develops diagnostic tests used in cancer care that indicate to doctors whether a tumor has been fully removed. The company operates in the oncology and women's health diagnostics space.
4 investors
Known Medicine develops a predictive engine using AI and patient datasets to identify optimal cancer treatments for individual patients. The company serves oncologists and cancer patients through computational analysis of biomaterials and drug-discovery data.
4 investors
Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
4 investors
GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.
2 investors
Omanta provides personalized scientific research support for complex disease cases, assigning PhD-level teams to build detailed molecular profiles from a patient's genomic, RNA, and protein data. It cross-references each patient's molecular profile against an internal reference cohort and biomedical literature to model therapeutic options and produce a research roadmap that informs the clinical team's decisions.</parameter> <parameter name="founders">[]
2 investors
SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.
2 investors
Zealth develops remote monitoring software that enables hospitals to track cancer patients after discharge and provide continuous automated support for managing treatment side effects and symptoms at home.
2 investors
Adventris is a biotechnology company developing cancer immunotherapy treatments.
1 investor
Eris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.
1 investor
Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.
1 investor
Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.
1 investor
Oncobox provides low-cost personalized genetic profiling that analyzes tumor DNA, RNA, and molecular pathways to recommend which targeted drugs are likely most effective for an individual late-stage cancer patient. It serves doctors and partners from pharma, hospitals, payers, and genomic centers in oncology.
1 investor
REPROSENT captures patient treatment experience data to support dose, safety, and development decisions in oncology and advanced cancer therapies. The platform operates as a lightweight, non-interventional overlay on existing clinical trials and care programs, converting patient symptoms into structured, computable signal for development and clinical teams.
1 investor





















